Zenas BioPharma, Inc.
ZBIO
Analytical Summary
Zenas BioPharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
100.0%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+1150%)
|
-90.0%
Weak
Weak
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-1225%)
|
— | — |
| EPS Growth YoY (%) |
29.0%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
51.0%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-140.6%
Weak
Weak
Year-over-year change in net income |
-322.9%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
57.5%
Excellent
Excellent
Year-over-year change in free cash flow |
54.5%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Operating Margin (%) (%) | — | — |
-74.3%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-595%)
|
— |
| Effective Tax Rate (%) (%) |
0.0%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.3%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.8%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| Profit Margin (%) (%) | — | — |
-74.2%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-719%)
|
— |
| FCF Margin (%) (%) | — | — |
-61.1%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
| FCF / Net Income (x) |
0.46x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.76x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.82x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-119.4%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-52.6%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
16.6%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-99.8%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-44.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-54.5%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-156.0%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1140%)
|
-50.2%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-435%)
|
16.4%
Good
Good
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+10%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Debt to Equity (x) |
0.32x
Good
Good
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-46%)
|
— | — | — |
| Net Debt (USD) | $-32.01M | $-319.74M | $-56.86M | — |
| Debt / EBITDA (x) |
-0.21x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— | — | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $10.00M | $5.00M | $50.00M | — |
| Depreciation Expense (USD) | $56.00K | $137.00K | $113.00K | — |
| Net Income, GAAP (USD) | $-377.74M | $-156.99M | $-37.12M | — |
| Operating Cash Flow (USD) | $-172.33M | $-119.67M | $-30.53M | — |
Secondary lens
Benchmark Lens
Compare ZBIO against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ZBIO against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for ZBIO
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How ZBIO compares to all companies
Peer Comparison
ZBIO vs similar peers
Compare ZBIO with peers
Stack ZBIO against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters